---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-034506"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2025-09-10T23:59:59+00:00"
generated_at: "2026-05-17T06:57:47.578455+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Gyre Therapeutics posts corporate presentation; no material financial or pipeline details provided

## Summary
- Updated corporate presentation posted on company website as of Sept 10, 2025.
- Presentation prepared for H.C. Wainwright Global Investment Conference in September 2025.
- Filing text and exhibit excerpt do not disclose any new financial data or pipeline milestones.
- Company focus remains anti-fibrotic therapeutics for chronic organ diseases.

## SEC filing metadata
- accession: 0001140361-25-034506
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2025-09-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036125034506/0001140361-25-034506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036125034506/ef20055378_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-034506
- JSON: https://secwatch.observer/filing/0001140361-25-034506.json
- Plain text: https://secwatch.observer/filing/0001140361-25-034506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.